Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.60 |
| ▸ | TYK2 | P29597 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.48 |
| ▸ | PLK1 | P53350 | 1/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2352415 | 0.84 | KDM4E (0.48) | NAPRTTYK2RAB9ANPC1GAA | |
| SCHEMBL6916843 | 0.82 | NAPRT (0.62) | NAPRTTYK2RAB9ANPC1GAA | |
| SCHEMBL109595 | 0.81 | NAPRT (0.60) | NAPRTTYK2RAB9ANPC1GAA | |
| SCHEMBL9936595 | 0.79 | GAA (0.61) | NAPRTGAAPLK1KDM4EMAPT | |
| SCHEMBL3182033 | 0.78 | NAPRT (0.67) | NAPRTTYK2RAB9ANPC1GAA | |
| SCHEMBL16982383 | 0.78 | NAPRT (0.51) | NAPRTTYK2RAB9ANPC1GAA | |
| SCHEMBL425117 | 0.77 | NAPRT (0.72) | NAPRTTYK2RAB9ANPC1GAA | |
| SCHEMBL8193694 | 0.77 | NAPRT (0.72) | NAPRTTYK2RAB9ANPC1GAA | |
| SCHEMBL680683 | 0.77 | NAPRT (0.60) | NAPRTTYK2GAAKDM4EMAPT | |
| SCHEMBL3368022 | 0.77 | TYK2 (0.70) | NAPRTTYK2RAB9ANPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1861371-A1 | NOVEL COMPOUNDS II 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE. | AstraZeneca AB (SE) | 2007-12-05 | — | — | EP | claimed |
| WO-2006098684-A1 | NOVEL COMPOUNDS II 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE. | ASTRAZENECA AB (SE) | 2006-09-21 | — | — | WO | claimed |
| CN-115697993-B | Pyrimidine compounds as AXL inhibitors | 南京正大天晴制药有限公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-115697993-A | Pyrimidines as AXL inhibitors | 南京正大天晴制药有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
| WO-2021011871-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| US-10442810-B2 | Pyrrolotriazine compounds as TAM inhibitors | INCYTE CORPORATION (US) | 2019-10-15 | — | — | US | disclosed |
| CN-108290866-A | 2- oxo -1,2- dihydropyridine -3,5- diformamide compounds as bromine structural domain inhibitor | 葛兰素史克知识产权第二有限公司 | 2018-07-17 | — | — | CN | disclosed |
| EP-3334458-A1 | COMBINATION THERAPY FOR CANCER | Imclone, LLC (US) | 2018-06-20 | — | — | EP | disclosed |
| CN-108137542-A | Pyridone diformamide as bromine structural domain inhibitor | 葛兰素史克知识产权第二有限公司 | 2018-06-08 | — | — | CN | disclosed |
| US-9981975-B2 | Pyrrolotriazine compounds as tam inhibitors | INCYTE CORPORATION (US) | 2018-05-29 | — | — | US | disclosed |
| US-7704998-B2 | anticancer agents; catalytic hydrogenation | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-27 | — | — | US | disclosed |
| EP-1485365-B1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-14 | — | — | EP | disclosed |
| US-20080108601-A1 | anticancer agents; catalytic hydrogenation | VAN EMELEN KRISTOF | 2008-05-08 | — | — | US | disclosed |
| US-20080108601-A1 | anticancer agents; catalytic hydrogenation | VAN EMELEN KRISTOF | 2008-05-08 | — | — | US | disclosed |
| US-20070142393-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | EMELEN KRISTOF V | 2007-06-21 | — | — | US | disclosed |
| US-20070142393-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | EMELEN KRISTOF V | 2007-06-21 | — | — | US | disclosed |
| US-7205304-B2 | medicine to inhibit proliferative conditions, such as cancer and psoriasis | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-17 | — | — | US | disclosed |
| US-7205304-B2 | medicine to inhibit proliferative conditions, such as cancer and psoriasis | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-17 | — | — | US | disclosed |
| EP-0204335-A2 | 2(1H)-Pyridin-ones useful as intermediates | STERLING DRUG INC. (US) | 1986-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10442810-B2 | Pyrrolotriazine compounds as TAM inhibitors | MERTK, MAP3K15, MAP3K5 | NAPRT 704/4885TYK2 213/4885RAB9A 2040/4885 |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, ITK, CRKL | NAPRT 331/4885TYK2 219/4885RAB9A 4545/4885 |
| US-20070142393-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC3, HDAC1, HDAC11 | NAPRT 1027/4885TYK2 2903/4885RAB9A 2186/4885 |
| US-20080108601-A1 | anticancer agents; catalytic hydrogenation | HDAC1, HDAC11, HDAC3 | NAPRT 1868/4885TYK2 3203/4885RAB9A 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.